Characterization of the Tumor Microenvironment and the Biological Processes with a Role in Prostatic Tumorigenesis

• Published in: Biomedicines 2022-07, Vol.10 (7), p.1672
• Main Authors: Ionescu, Cristina-Anita, Aschie, Mariana, Matei, Elena, Cozaru, Georgeta Camelia, Deacu, Mariana, Mitroi, Anca Florentina, Baltatescu, Gabriela Isabela, Nicolau, Antonela-Anca, Mazilu, Laura, Tuta, Liliana Ana, Iorga, Ionut Ciprian, Stanigut, Alina, Enciu, Manuela
• Format: Article
• Language: English
• Subjects: Adenocarcinoma; Aneuploidy; Apoptosis; Biomarkers; Blood platelets; CD34; CD34 antigen; CD42b glycoproteins; CD61; Cell adhesion; Cell adhesion & migration; Cell cycle; Cell growth; Cell proliferation; Chromosomes; Cloning; Cytometry; Flow cytometry; Gene expression; Glycoproteins; Hyperplasia; Immunohistochemistry; Infiltration; Kinases; Lymphocytes; Lymphocytes T; Medical prognosis; Mesenchyme; Metastases; Metastasis; Monoclonal antibodies; Patients; Population; Prostate; Prostate cancer; prostate carcinogenesis; Statistical analysis; Tumor microenvironment; Tumorigenesis; Tumors
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines10071672

Prostate intratumoral heterogeneity, driven by epithelial−mesenchymal plasticity, contributes to the limited treatment response, and it is therefore necessary to use the biomarkers to improve patient prognostic survival. We aimed to characterize the tumor microenvironment (T lymphocyte infiltration, intratumoral CD34, and KI-67 expressions) by immunohistochemistry methods and to study the biological mechanisms (cell cycle, cell proliferation by adhesion glycoproteins, cell apoptosis) involved in the evolution of the prostate tumor process by flow-cytometry techniques. Our results showed that proliferative activity (S-phase) revealed statistically significant lower values of prostate adenocarcinoma (PCa) and benign prostatic hyperplasia (BPH) reported at non-malignant adjacent cell samples (PCa 4.32 ± 4.91; BPH 2.35 ± 1.37 vs. C 10.23 ± 0.43, p < 0.01). Furthermore, 68% of BPH cases and 88% of patients with PCa had aneuploidy. Statistically increased values of cell proliferation (CD34+ CD61+) were observed in prostate adenocarcinoma and hyperplasia cases reported to non-malignant adjacent cell samples (PCa 28.79 ± 10.14; BPH 40.65 ± 11.88 vs. C 16.15 ± 2.58, p < 0.05). The CD42b+ cell population with a role in cell adhesion, and metastasis had a significantly increased value in PCa cases (38.39 ± 11.23) reported to controls (C 26.24 ± 0.62, p < 0.01). The intratumoral expression of CD34 showed a significantly increased pattern of PCa tissue samples reported to controls (PCa 26.12 ± 6.84 vs. C 1.50 ± 0.70, p < 0.01). Flow cytometric analysis of the cell cycle, apoptosis, and adhesion glycoproteins with a critical role in tumoral cell proliferation, T cell infiltrations, Ki-67, and CD 34 expressions by IHC methods are recommended as techniques for the efficient means of measurement for adenocarcinoma and hyperplasia prostate tissue samples and should be explored in the future.